<DOC>
	<DOCNO>NCT00562068</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , alemtuzumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop grow . Giving alemtuzumab together combination chemotherapy may kill cancer cell . PURPOSE : This phase I trial study side effect best dose alemtuzumab give together combination chemotherapy see well work treat patient stage I , stage II , stage III , stage IV peripheral T-cell lymphoma .</brief_summary>
	<brief_title>Alemtuzumab Combination Chemotherapy Treating Patients With Stage I , Stage II , Stage III , Stage IV Peripheral T-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine feasibility add alemtuzumab standard cyclophosphamide , doxorubicin hydrochloride , vincristine , oral prednisolone ( CHOP ) chemotherapy patient stage I-IV peripheral T-cell lymphoma ( PTCL ) . - To assess side effect profile early late toxicity regimen standard dose-escalation design , establish appropriate dose level future study . Secondary - To document response rate disease-free survival patient treated regimen , compare finding historical control . - To monitor immune reconstitution therapy . - To determine pharmacokinetics subcutaneous alemtuzumab give combination CHOP chemotherapy . - To clearly define CD52 expression profile tumor investigate phenotypic variation PTCL . - To document change ( ) level Epstein-Barr virus copy number polymerase chain reaction CHOP-alemtuzumab therapy . OUTLINE : This multicenter , dose escalation alemtuzumab study . Patients receive CHOP chemotherapy comprise cyclophosphamide IV , doxorubicin hydrochloride IV , vincristine IV day 1 oral prednisone day 1-5 . Patients also receive alemtuzumab subcutaneously ( SC ) 1-3 time week 6 dos per course . Treatment repeat every 3 week 8 course absence disease progression unacceptable toxicity . Patients undergo blood collection baseline , periodically study treatment , completion study therapy pharmacokinetics correlative study monitor cellular immunity . Blood sample examine polymerase chain reaction detect cytomegalovirus antigen monitor Epstein-Barr virus copy number . Samples also analyze flow cytometry quantify circulate B- T-cells , NK-cells , monocytes , dendritic-cells . After completion study therapy , patient follow every 3 month first year , every 6 month second year , yearly thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis peripheral Tcell lymphoma ( PTCL ) , include follow subtypes : PTCL otherwise specify Angioimmunoblastic Tcell lymphoma Anaplastic lymphoma kinasenegative anaplastic large cell lymphoma Intestinal Tcell lymphoma Bulky stage IA stag IBIV disease ( Ann Arbor stag system ) Expression CD52 tumor Measurable evaluable disease No anaplastic lymphoma kinasepositive anaplastic largecell lymphoma No CNS involvement nonHodgkin lymphoma PATIENT CHARACTERISTICS : WHO performance status 02 No presence serious , uncontrolled medical condition No significant anthracyclinerelated cardiac impairment LVEF ≥ 50 % Creatinine ≤ 1.5 mg/dL Bilirubin ≤ 2 time normal value unless due disease Not pregnant nursing Fertile patient must use effective barrier contraception 1 month completion study treatment No previous malignancy except adequately treat nonmelanoma skin cancer cervical intraepithelial neoplasia No positive serology nonconsenting test following : HIV Hepatitis B C Human Tlymphotropic virus type 1 ( HTLV1 ) PRIOR CONCURRENT THERAPY : No prior cytotoxic chemotherapy Prior radiotherapy may allow trial coordinator 's discretion Concurrent consolidation radiotherapy may give clinician 's discretion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>peripheral T-cell lymphoma</keyword>
</DOC>